Constipation Clinical Trial
Official title:
Percutaneous Tibial Nerve Stimulation and Pelvic Floor Rehabilitation in the Treatment of Childhood Constipation
NCT number | NCT05059756 |
Other study ID # | A333 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 8, 2019 |
Est. completion date | December 8, 2021 |
Verified date | November 2023 |
Source | Shengjing Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Constipation is the most common complaint in childhood, affecting an estimated 20% of children globally. At present, the treatment of children's constipation is full of challenges, and treatment methods are diverse. Studies have shown that pelvic floor dysfunction is a common cause of intractable constipation in children. Zhang et al. have confirmed the role of pelvic floor dysfunction in pediatric constipation. At present, the main methods for pelvic floor dysfunction include surface electromyography and anorectal manometry which have been widely used in children with constipation and they are helpful for the diagnosis of pelvic floor dysfunction in children with constipation. Sacral nerve electrical stimulation combined with pelvic floor rehabilitation is an effective method for the treatment of pelvic floor dysfunction. It offers a novel approach for the treatment of intractable constipation with pelvic floor dysfunction . At present, there are many methods for sacral nerve regulation. Percutaneous tibial nerve stimulation (PTNS), another peripheral nerve electrical stimulation approved by the United States Food and Drug Administration, has the same effect as sacral nerve regulation, and has the advantages of small trauma, safety, and convenience. However, there is still a lack of evidence-based support for the treatment of childhood constipation by PTNS combine with PFR. Therefore, in this study, a randomized, controlled, double-blind clinical trial was designed to confirm the efficacy and safety of PTNS combine with PFR in the treatment of childhood constipation.
Status | Completed |
Enrollment | 84 |
Est. completion date | December 8, 2021 |
Est. primary completion date | December 8, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 14 Years |
Eligibility | Inclusion Criteria: - 4-14 years old; - Meeting the Roman IV criteria for childhood constipation; - After one course of PEG and one course of Chinese medicine treatment, it was ineffective; - Pelvic floor surface electromyography (EMG) and 3-D manometry of the anus revealed pelvic floor dysfunction Exclusion Criteria:meet one of the following criteria to be excluded: - The onset of intestinal stenosis due to organic diseases (such as anal fissure, inflammation, intestinal polyps, intestinal adhesion, Crohn's disease, intestinal tuberculosis, tumor, etc.); - constipation due to congenital diseases (such as congenital megacolon, sigmoid colon, etc.); - Caused by metabolic endocrine diseases, neurological diseases and mental diseases; - Those caused by systemic organic diseases; - Patients diagnosed as outlet obstructive constipation and mixed functional constipation; - Children with severe systemic diseases; - Children with positive occult blood in stool routine examination; - Children who refused to participate in PTNS combined with PFR. |
Country | Name | City | State |
---|---|---|---|
China | Shengjing Hospital | Shenyang | Liaoning |
Lead Sponsor | Collaborator |
---|---|
Shengjing Hospital |
China,
Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. In — View Citation
Zar-Kessler C, Kuo B, Cole E, Benedix A, Belkind-Gerson J. Benefit of Pelvic Floor Physical Therapy in Pediatric Patients with Dyssynergic Defecation Constipation. Dig Dis. 2019;37(6):478-485. doi: 10.1159/000500121. Epub 2019 May 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change of CSBMs (sub/week) from baseline | Rate of defecation without drugs or other auxiliary methods | Baseline | |
Primary | change of CSBMs (sub/week) from baseline | Rate of defecation without drugs or other auxiliary methods | at the end of 4-weeks PTNS and PFR treatment | |
Primary | change of CSBMs (sub/week) from baseline | Rate of defecation without drugs or other auxiliary methods | at the end of 12 weeks follow-up | |
Primary | Satisfaction with bowel function | Satisfaction with bowel function was collected from the parents and defined as the number of which were satisfied with bowel function after the treatment (yes or no). | Baseline | |
Primary | Satisfaction with bowel function Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no). | Satisfaction with bowel function was collected from the parents and defined as the number of which were satisfied with bowel function after the treatment (yes or no). | at the end of 4-weeks PTNS and PFR treatment | |
Primary | Satisfaction with bowel function Satisfaction with bowel function was collected from the parents and defined as the number of which were satisfied with bowel function after the treatment (yes or no). | Satisfaction with bowel function was collected from the parents and defined as the number of which were satisfied with bowel function after the treatment (yes or no). | at the end of 12 weeks follow-up | |
Secondary | Bowel movements the frequency of bowel movements per week | Rate of bowel movements per week;Incidence of constipation. | Baseline | |
Secondary | Bowel movements | Rate of bowel movements per week;Incidence of constipation. | at the end of 4-weeks PTNS and PFR treatment | |
Secondary | Bowel movements | Rate of bowel movements per week;Incidence of constipation. | at the end of 12 weeks follow-up | |
Secondary | Painful or hard bowel movements | The feelings of children during defecation;Rate of painful or hard bowel movements. | Baseline | |
Secondary | Painful or hard bowel movements | The feelings of children during defecation;Rate of painful or hard bowel movements. | at the end of 4-weeks PTNS and PFR treatment | |
Secondary | Painful or hard bowel movements | The feelings of children during defecation;Rate of painful or hard bowel movements. | at the end of 12 weeks follow-up | |
Secondary | Large diameter or scybalous stools | Appearance and wetness of stool; Rate of patients with large diameter or scybalous stools. | Baseline | |
Secondary | Large diameter or scybalous stools | Appearance and wetness of stool; Rate of patients with large diameter or scybalous stools. | at the end of 4-weeks PTNS and PFR treatment | |
Secondary | Large diameter or scybalous stools | Appearance and wetness of stool; Rate of patients with large diameter or scybalous stools. | at the end of 12 weeks follow-up | |
Secondary | Excessive volitional stool retention | Rate of children who intentionally control or reduce the frequency of defecation. | Baseline | |
Secondary | Excessive volitional stool retention | Rate of children who intentionally control or reduce the frequency of defecation. | at the end of 4-weeks PTNS and PFR treatment | |
Secondary | Excessive volitional stool retention | Rate of children who intentionally control or reduce the frequency of defecation. | at the end of 12 weeks follow-up | |
Secondary | Encopresis | Incidence of fecal incontinence | Baseline | |
Secondary | Encopresis | Incidence of fecal incontinence | at the end of 4-weeks PTNS and PFR treatment | |
Secondary | Encopresis | Incidence of fecal incontinence | at the end of 12 weeks follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 |